CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma

• Main Authors: de Larrea, C.F (Author), Engel, P. (Author), García, J.F (Author), García-González, Á (Author), Jiménez, S. (Author), Maestre, L. (Author), Mena, M.-P (Author), Montes-Moreno, S. (Author), Piris, M.Á (Author), Puñet-Ortiz, J. (Author), Reyes-García, A.I (Author), Rodríguez-Justo, M. (Author), Rodríguez-Lobato, L.G (Author), Roncador, G. (Author)
• Format: Article
• Language: English
• Published: MDPI 2022
• Subjects: B cells; CD229; leukemia; Ly9; lymphoma; myeloma; soluble receptor
• Online Access: View Fulltext in Publisher

 CD229 (Ly9) homophilic receptor, which belongs to the SLAM family of cell-surface molecules, is predominantly expressed on B and T cells. It acts as a signaling molecule, regulating lymphocyte homoeostasis and activation. Studies of CD229 function indicate that this receptor functions as a regulator of the development of marginal-zone B cells and other innate-like T and B lymphocytes. The expression on leukemias and lymphomas remains poorly understood due to the lack of CD229 monoclonal antibodies (mAb) for immunohistochemistry application (IHC). In this study, we used a new mAb against the cytoplasmic region of CD229 to study the expression of CD229 on normal tissues and B-cell malignancies, including multiple myeloma (MM), using tissue microarrays. We showed CD229 to be restricted to hematopoietic cells. It was strongly expressed in all cases of MM and in most marginal-zone lymphomas (MZL). Moderate CD229 expression was also found in chronic lymphocyte leukemia (CLL), follicular (FL), classic mantle-cell (MCL) and diffuse large B-cell lymphoma. Given the high expression on myeloma cells, we also analyzed for the presence of soluble CD229 in the sera of these patients. Serum levels of soluble CD229 (sCD229) at the time of diagnosis in MM patients could be useful as a prognostic biomarker. In conclusion, our results indicate that CD229 represents not only a useful biomarker but also an attractive therapeutic target. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.